Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering

Xenetic Biosciences, Inc.

2025-Q3 EPS reported -$1.36 revenue$2,210,115

Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.
R&D expenses increased 105.6% to $0.8M due to manufacturing and pre-clinical work; G&A rose 9.3% to $0.8M on legal costs.
Cash at Sept 30, 2025 was ~$4.1M; subsequent October 2025 offering added ~$3.9M net proceeds, extending runway.
DNase I program advancing toward IND submission and Phase 1 for pancreatic and solid tumors; preclinical studies ongoing.
PeriNess agreement for investigator-initiated studies in Israeli centers under regulatory approval process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.